secret
polypeptid
prokaryot
eukaryot
cell
elabor
mechan
enabl
execut
essenti
process
like
activ
modul
environ
enzymat
process
nutrient
commun
cell
howev
uniqu
group
secret
polypeptid
secret
toxin
play
differ
role
maintain
fit
organ
perfect
evolut
aim
damag
live
organ
toxin
provid
produc
advantag
enhanc
defens
capabl
pathogen
compet
natur
protein
toxin
divid
three
major
group
toxin
damag
cell
disrupt
membran
integr
toxin
disrupt
normal
electr
activ
nervou
system
intox
organ
toxin
disrupt
interfer
cellular
process
virtu
enzymat
activ
member
group
may
affect
target
cell
enzymat
nonenzymat
activ
member
third
group
review
focus
extrem
toxic
polypeptid
capabl
self
transloc
cell
cytoplasm
execut
activ
case
lead
death
intox
cell
scientif
advanc
last
decad
facilit
process
manipul
biolog
substanc
among
toxic
polypeptid
encod
gene
use
differ
strategi
direct
toxic
moieti
diseas
cellstissu
figur
scientist
establish
new
nich
clinic
research
call
toxinbas
therapi
follow
review
provid
highlight
sever
promin
studi
field
product
studi
evalu
clinic
current
undergo
clinic
evalu
mostli
context
oncolog
diseas
construct
classifi
target
strategi
use
name
surfac
antigenreceptor
specif
target
immunotoxin
transcript
target
suicid
gene
proteas
specif
target
proteas
activ
toxin
emphasi
put
construct
toxic
moieti
deriv
bacteri
toxin
produc
corynebacterium
diphtheria
diphtheria
toxin
pseudomona
aeruginosa
pseudomona
exotoxin
bacillu
anthrachi
anthrax
toxin
plant
produc
toxin
ribosom
inactiv
protein
recent
review
botulinum
toxin
bacteri
neurotoxin
commonli
appli
today
medicin
cover
follow
page
see
diphtheria
toxin
dt
secret
pathogen
strain
bacterium
corynebacterium
diphtheria
prototyp
famili
adpribosyl
toxin
belong
group
toxin
call
ab
toxin
consist
two
fragment
b
b
fragment
respons
cell
entri
bind
cell
surfac
receptor
subsequ
transloc
cell
cytoplasm
intern
fragment
intox
cell
virtu
enzymat
activ
toxin
secret
singl
protein
amino
acid
compos
three
function
domain
n
termin
domain
residu
repres
catalyt
c
fragmentdomain
dtadta
c
termin
portion
toxin
amino
acid
repres
b
fragment
divid
two
function
domain
transloc
domain
amino
acid
receptor
bind
domain
r
amino
acid
nativ
diphtheria
toxin
bind
via
r
domain
heparin
bind
epiderm
growth
factor
precursor
cell
membran
cleav
cellsurfac
furin
furinlik
proteas
dichain
protein
still
link
singl
bond
cystein
cystein
intern
clathrin
coat
pit
reach
lumen
develop
endosom
furinmedi
cleavag
toxin
molecul
escap
cleavag
cellsurfac
proteas
may
occur
upon
endosom
acidif
domain
undergo
conform
chang
lead
exposur
hydrophob
area
insert
membran
form
channel
catalyt
domain
transloc
escap
endosom
probabl
aid
cytosol
factor
cell
cytoplasm
catalyt
domain
exert
toxic
activ
transfer
adenosin
diphosphateribos
adpribos
moieti
nicotinamid
dinucleotid
nad
modifi
histidin
residu
diphthamid
posit
eukaryot
translat
elong
factor
action
result
inactiv
latter
inhibit
protein
synthesi
program
cell
death
figur
also
report
deliveri
singl
molecul
catalyt
domain
cytosol
suffici
kill
cell
demonstr
extrem
potenc
bacteri
toxin
denileukin
diftitox
also
name
ontak
fusion
protein
design
direct
truncat
form
diphtheria
toxin
cell
express
highaffin
receptor
consist
follow
subunit
present
mani
differ
hematolog
malign
like
adult
cell
leukemia
atl
chronic
lymphocyt
leukemia
hodgkin
nonhodgkin
lymphoma
cutan
cell
lymphoma
ctcl
leukemia
lymphoma
immunotoxin
compris
genet
fusion
truncat
form
dt
first
amino
acid
natur
receptor
bind
domain
toxin
replac
cytokin
phase
test
conduct
patient
tcell
lymphoma
ctcl
n
nonhodgkin
lymphoma
nhl
hodgkin
diseas
hd
n
drug
administr
intraven
infus
produc
five
complet
cr
eight
partial
pr
remiss
patient
ctcl
one
cr
two
pr
occur
nhl
respons
document
patient
hd
doselimit
toxic
trial
asthenia
pivot
phase
iii
trial
patient
ctcl
treat
denileukin
diftitox
object
respons
partial
respons
complet
respons
sinc
fda
approv
ontak
first
immunotoxin
treatment
advanc
ctcl
drug
test
treatment
malign
nonmalign
diseas
like
bcell
nhl
bcell
chronic
lymphocyt
leukemia
ccl
panniculit
lymphoma
psoriasi
graftversushost
diseas
gvhd
respons
observ
trial
major
acut
myeloid
leukemia
aml
blast
cell
express
granulocytemacrophag
colonystimul
factor
gmcsf
receptor
order
target
cancer
cell
human
gmcsf
fuse
truncat
dt
toxin
replac
natur
receptor
bind
domain
result
molecul
dtgm
test
patient
resist
chemotherapi
among
one
complet
remiss
two
partial
remiss
follow
treatment
drug
administr
intraven
iv
infus
liver
failur
transient
hepat
encephalopathi
observ
two
patient
possibl
result
inflammatori
cytokin
releas
liver
kupffer
cell
directli
bind
damag
hepatocyt
transferrin
receptor
tfr
overexpress
rapidli
divid
cell
variou
tumor
cell
rel
scarc
healthi
brain
tissu
intens
express
tfr
found
tumor
cell
glioblastoma
multiform
gbm
also
call
transmid
conjug
protein
mutant
diphtheria
toxin
lack
receptorbind
activ
link
thioester
bond
human
transferrin
tf
phase
clinic
trial
deliv
highflow
interstiti
microinfus
tumor
region
reduct
tumor
volum
occur
nine
patient
could
evalu
includ
two
complet
respons
symptomat
system
toxic
occur
phase
ii
clinic
studi
treatment
result
respons
rate
patient
evalu
efficaci
total
five
complet
respond
seven
partial
respond
infus
result
symptomat
progress
cerebr
edema
eight
total
enrol
patient
respons
medic
manag
seizur
seen
three
patient
respond
anticonvuls
therapi
howev
condit
power
analysi
phase
iii
determin
unlik
improv
overal
patient
surviv
compar
current
standard
care
decid
termin
trial
clinic
develop
drug
pseudomona
exotoxin
abbrevi
pe
eta
amino
acid
polypeptid
secret
bacterium
pseudomona
aeruginosa
one
virul
factor
like
diphtheria
toxin
belong
famili
adpribosyl
toxin
group
ab
toxin
see
descript
diphtheria
toxin
toxin
divid
three
main
structur
function
domain
ntermin
domain
ia
aa
respons
cell
recognit
domain
ii
aa
requir
transloc
toxin
across
cellular
membran
exact
function
structur
domain
ib
aa
fulli
understood
last
four
residu
aa
domain
ib
togeth
domain
iii
aa
form
catalyt
subunit
protein
ctermin
lysin
remov
plasma
carboxypeptidas
leav
terminu
redl
toxin
bind
via
cellbind
domain
ia
also
call
receptorlowdens
lipoprotein
receptorrel
protein
surfac
cell
toxin
intern
enter
earli
endosom
mainli
via
clathrinco
pit
also
via
caveosom
follow
associ
detergentresist
microdomain
acid
environ
endosom
pe
dissoci
receptor
undergo
conform
chang
cleav
cellular
proteas
furin
furinsensit
loop
domain
ii
toxin
follow
reduct
singl
disulfid
bond
hold
proteolyt
fragment
togeth
enzymat
activ
c
kda
fragment
travel
rout
transgolgi
network
tgn
c
termin
expos
sequenc
redl
bind
kdel
intracellular
sort
receptor
fragment
travel
endoplasm
reticulum
er
altern
lipid
sort
er
may
occur
er
sequenc
transloc
domain
ii
mediat
transloc
kda
fragment
cytoplasm
process
probabl
involv
subvers
erassoci
degrad
erad
pathway
retrograd
transport
via
translocon
escap
least
part
proteosom
degrad
may
attribut
low
lysin
content
enzymat
activ
c
termin
kda
fragment
cytosol
apdribosyl
enzymat
activ
domain
iii
inactiv
similar
way
diphtheria
toxin
see
lead
protein
synthesi
inhibit
program
cell
death
figur
construct
pebas
immunotoxin
receptor
bind
domain
ia
replac
antibodi
antibodi
deriv
ligand
preferenti
bind
tumorassoci
antigenreceptor
result
truncat
form
pe
design
indic
molecular
weight
kda
addit
larg
part
domain
ib
delet
without
effect
cytotox
gener
smaller
form
modifi
toxin
denot
kda
order
target
express
cell
lowaffin
receptor
see
regardless
presenc
subunit
gener
express
much
greater
extent
rel
malign
cell
type
fuse
singlechain
form
monoclon
antibodi
antitac
result
immunotoxin
demonstr
promis
result
preclin
trial
toward
cell
tumor
xenograft
nude
mice
phase
trial
administr
intraven
patient
chemotherapyresist
leukemia
lymphoma
hd
result
complet
partial
remiss
common
toxic
includ
transaminas
elev
associ
fever
possibl
outcom
cytokin
releas
six
patient
made
neutral
antibodi
one
cycl
prevent
receiv
phase
ii
trial
patient
metastat
melanoma
administr
led
transient
partial
reduct
circul
tumorinfiltr
treg
cell
abl
suppress
abil
vaccin
selftumor
antigen
howev
therapi
augment
immun
respons
peptid
base
cancer
vaccin
phase
ii
trial
current
underway
patient
chronic
lymphocyt
leukemia
cll
cutan
cell
lymphoma
ctcl
hairi
cell
leukemia
hcl
phosphoglycoprotein
adhes
molecul
present
surfac
b
cell
includ
human
bcell
lymphoma
leukemia
dsfv
stabl
immunotoxin
target
express
cell
compos
disulfid
stabil
fv
region
dsfv
monoclon
antibodi
fuse
clinic
trial
iv
administr
adult
hairi
cell
leukemia
resist
purin
analogu
therapi
produc
promis
result
complet
remiss
six
partial
respons
patient
phase
complet
remiss
partial
respons
one
cycl
treatment
phase
ii
n
common
toxic
includ
hypoalbuminemia
transaminas
elev
fatigu
edema
revers
grade
hemolyt
urem
syndrom
requir
plasmapheresi
recent
phase
clinic
trial
conduct
pediatr
subject
lymphoma
show
treatment
associ
accept
safeti
profil
advers
event
rapidli
revers
maximum
toler
dose
defin
although
respons
observ
transient
clinic
activ
seen
subject
lewi
ley
type
blood
group
relat
oncofet
carbohydr
antigen
express
nearli
human
epitheli
carcinoma
immunotoxin
consist
monoclon
antibodi
conjug
phase
clinic
trial
immunotoxin
test
patient
ley
express
carcinoma
breast
ovarian
colon
esophagu
stomach
ampulla
vater
complet
remiss
observ
patient
metastat
breast
cancer
greater
tumor
reduct
observ
colon
cancer
patient
follow
system
administr
immunotoxin
major
toxic
vascular
leak
syndrom
ascrib
endotheli
damag
probabl
due
bind
antibodi
ley
antigen
present
small
amount
endotheli
cell
later
develop
lewi
target
toxin
produc
recombin
immunotoxin
fv
dsfv
clinic
evalu
patient
lewi
yexpress
malign
howev
signific
antitumor
activ
observ
trial
ribosom
inactiv
protein
rip
group
glycosyl
nonglycosyl
enzym
nglycosidas
activ
initi
detect
higher
plant
also
found
fungi
alga
bacteria
comprehens
review
see
rip
may
present
one
tissu
plant
express
enhanc
senesc
variou
stress
condit
includ
microorgan
viral
infect
rip
artifici
divid
three
group
basi
structur
mode
activ
type
rip
singl
chain
basic
protein
kda
enzymat
activ
well
known
member
group
saporin
saponaria
officinali
pokewe
antivir
protein
pap
phytolacca
americana
gelonin
gelonium
multiforum
type
ii
rip
like
ricin
ricinu
communi
abrin
abru
precatoriu
heterodimer
protein
consist
enzymat
activ
chain
kda
link
disulfid
bond
b
chain
approxim
kda
properti
lectin
type
iii
rip
like
maiz
barley
protein
respect
synthes
inact
precursor
prorip
lack
lectin
moieti
activ
proteolyt
process
includ
remov
termin
sequenc
short
inhibitori
intern
peptid
ricin
prototyp
type
ii
rip
glycosyl
heterodim
bind
lectin
galactos
nacetylgalactosamin
residu
glycoprotein
glycolipid
present
surfac
eukaryot
cell
addit
certain
cell
like
macrophag
rat
liver
endotheli
cell
express
surfac
mannos
receptor
demonstr
bind
ricin
also
oligosaccharid
side
chain
cell
surfacebound
ricin
intern
clathrindepend
well
clathrinindepend
endocytosi
travel
backward
golgi
er
disulfid
link
chain
separ
protein
disulfid
isomeras
case
pe
ricin
thought
subvert
erad
pathway
exploit
retrograd
transport
enzymat
activ
chain
rta
cell
cytosol
translocon
pauciti
lysin
rta
may
escap
least
part
degrad
proteosom
figur
type
type
iii
rip
lack
cellbind
lectin
b
chain
thu
gener
much
less
toxic
type
ii
rip
howev
like
ricin
glycosyl
type
rip
may
bind
carbohydr
receptor
cell
surfac
bind
type
rip
low
densiti
lipoprotein
ldl
receptor
relat
protein
also
bind
pe
also
demonstr
addit
coupl
type
rip
equival
enzymat
activ
chain
type
ii
rip
carrier
capabl
bind
cell
render
conjug
highli
cytotox
specif
mechan
type
rip
gain
entri
cell
cytosol
remain
unclear
probabl
differ
type
ii
rip
like
ricin
experi
type
rip
saporin
indic
reli
golgimedi
retrograd
transport
erad
may
involv
toxin
transloc
cytoplasm
endosom
cytosol
enzymat
moieti
rip
irrevers
damag
ribosom
remov
specif
adenin
correspond
residu
rat
rrna
gaga
sequenc
conserv
rrna
loop
call
sarcinricin
loop
modif
render
ribosom
unabl
interact
elong
factor
result
inhibit
translat
ultim
apoptot
cell
death
addit
classic
ribosomeinactiv
glycosidas
activ
activ
enzymat
properti
associ
rip
antivir
activ
depurin
nonribosom
rna
adenin
dna
glycosylas
activ
deoxyribonucleas
activ
ribonucleas
activ
remov
adenin
poli
adpribosyl
ate
poli
adpribos
polymeras
enzym
involv
dna
repair
depurin
cap
rna
templat
superoxid
dismutas
sod
activ
phospholipas
activ
involv
nonclass
rip
activ
cytotox
debat
though
accumul
evid
suggest
ribosom
inactiv
sole
mean
rip
execut
toxic
effect
lymphoid
activ
marker
highli
express
surfac
hodgkin
lymphoma
cell
present
minor
normal
human
cell
order
target
cell
two
immunotoxin
construct
toxic
moieti
immunotoxin
chemic
deglycosyl
form
ricin
chain
dga
deglycosyl
demonstr
minim
nonspecif
carbohydratereceptor
mediat
uptak
rta
base
immunotoxin
reticuloendotheli
cell
liver
link
target
moieti
monoclon
antibodi
respect
phase
iii
trial
iv
administr
patient
refractori
hodgkin
diseas
hd
result
two
partial
remiss
pr
one
minor
respons
mr
five
stabl
diseas
sd
phase
studi
patient
one
pr
one
mr
two
sd
observ
doselimit
toxic
relat
vascular
leak
syndrom
consist
edema
tachycardia
dyspnea
weak
myalgia
phase
ii
studi
evalu
side
effect
effici
treatment
patient
relaps
refractori
cutan
tcell
nonhodgkin
lymphoma
ctcl
complet
recent
immunotoxin
current
evalu
treatment
metastat
melanoma
http
clinicaltrialsgov
cell
surfac
glycoprotein
express
normal
malign
b
cell
target
bcell
lymphoma
cell
anti
monoclon
antibodi
anti
monoclon
antibodi
conjug
dga
phase
clinic
trial
immunotoxin
five
evalu
patient
bcell
lymphoma
show
partial
respons
one
show
complet
respons
similar
result
obtain
drug
administr
continu
infus
instead
intermitt
bolu
partial
complet
respons
also
obtain
phase
trial
patient
nonhodgkin
bcell
lymphoma
treat
immunotoxin
vascular
leak
syndrom
vl
common
doserel
toxic
studi
prostat
cancer
pca
common
cancer
diagnos
men
lead
caus
cancer
death
normal
malign
prostat
epithelia
specif
express
kallikrein
proteas
prostatespecif
antigen
psa
serin
proteas
trypsin
chymotrypsinlik
activ
respons
liquifact
semen
psa
gene
regulatori
region
prime
candid
direct
prostatespecif
express
place
transcript
regul
psa
promot
diphtheria
toxin
chain
dta
encod
gene
deliv
adenovir
vector
show
strong
inhibit
tumor
growth
psaproduc
prostat
tumor
xenograft
mous
model
affect
nonpsa
produc
tumor
xenograft
psa
promoterbas
lentivir
vector
also
use
mean
dta
gene
deliveri
lead
specif
erad
prostat
tumor
xenograft
nude
mice
follow
singl
intratumor
inject
repetit
inject
shown
inhibit
growth
recurr
tumor
anoth
studi
nanoparticul
system
base
cation
poli
bamino
ester
polym
use
dna
deliveri
system
suicid
gene
encod
diphtheria
toxin
chain
dta
transcript
regul
prostatespecif
modifi
human
psa
promot
psebc
genet
materialcation
polym
complex
local
deliv
normal
prostat
prostat
tumor
mice
caus
massiv
apoptot
prostat
cell
death
without
damag
surround
tissu
order
gain
tighter
control
express
potent
dta
toxin
peng
et
al
util
dual
express
control
system
reli
transcript
regul
dna
recombin
basi
system
chimer
modifi
enhancerpromot
sequenc
human
prostatespecif
antigen
psa
gene
psebc
use
regul
express
saccharomyc
cerevisia
plasmid
deriv
sitedirect
flp
recombinas
prostat
specif
express
flp
recombinas
occur
site
direct
dna
recombin
lead
dta
gene
express
take
place
investig
show
erad
psaexpress
normal
prostat
cell
prostat
cancer
cell
cultur
xenograft
transgen
mous
model
follow
adenovir
deliveri
dna
encod
prostat
specif
promoterdriven
flp
recombinas
flprespons
dta
gene
furthermor
flp
recombinas
express
shown
regul
manner
correl
amount
psa
express
cell
ovarian
cancer
common
malign
women
caus
death
type
femal
reproduct
tract
cancer
lidor
et
al
demonstr
specif
protein
synthesi
inhibit
malign
ovarian
cell
line
transfect
plasmid
encod
transcript
regul
diphtheria
dta
toxic
gene
transcript
regul
element
human
chorion
gonadotropin
hcg
promot
heterodimer
glycoprotein
placent
hormon
involv
differ
pregnancypromot
process
although
princip
produc
trophoblast
hcg
also
express
malign
tumor
ovari
uteru
testi
colon
liver
pancrea
lung
stomach
target
express
dta
ovarian
cancer
cell
vitro
tumor
cell
mous
model
perform
huang
et
al
use
poli
hamino
ester
polym
vector
nanoparticul
deliveri
dna
ovarianspecif
antitumor
construct
promot
two
gene
msln
transcript
activ
significantli
enhanc
ovarian
cancer
cell
rel
normal
ovarian
cell
cell
tissu
chosen
target
express
dta
gene
ovarian
tumor
cell
signific
reduct
tumor
mass
prolong
life
span
xenograft
bear
mice
observ
result
dta
nanoparticl
administr
directli
subcutan
xenograft
tumor
periton
caviti
moreov
treatment
dta
nanoparticl
result
effici
suppress
tumor
growth
compar
clinic
relev
dose
standard
chemotherapeut
cisplatin
paclitaxel
minim
nonspecif
tissu
blood
chemistri
toxic
recent
mizrahi
et
al
report
use
transcript
regulatori
sequenc
gene
drive
express
dta
specif
ovarian
tumor
cell
patern
imprint
matern
express
oncofet
gene
encod
rna
act
riboregul
without
protein
product
express
substanti
level
sever
differ
human
tumor
type
includ
epitheli
ovarian
cancer
margin
express
normal
adult
tissu
cation
polym
pei
base
deliveri
plasmid
encod
toxic
transcript
control
regulatori
sequenc
gene
show
high
kill
potenti
ovarian
cancer
cell
line
signific
tumor
growth
inhibit
anim
later
case
studi
plasmid
intraperiton
inject
peritoneum
woman
advanc
recurr
ovarian
carcinoma
report
yield
complet
resolut
ascit
follow
sever
infus
minimum
advers
event
phase
iii
studi
administ
intraperiton
subject
advanc
stage
ovarian
cancer
evid
symptomat
ascit
current
ongo
bladder
cancer
second
common
urolog
malign
prostat
cancer
estim
bladder
cancer
account
new
case
cancer
cancerrel
death
unit
state
one
crucial
enzym
cell
immort
cancer
telomeras
maintain
telomer
length
stabil
almost
cancer
cell
essenti
conserv
core
compon
human
telomeras
includ
revers
transcriptas
protein
famili
member
htert
telomeras
rna
hter
follow
situ
hybrid
analysi
show
high
level
hter
htert
express
bladder
tumor
signal
detect
normal
tissu
transcript
regulatori
element
two
gene
use
target
gene
therapi
purpos
drive
express
toxic
dta
gene
bladder
cancer
cell
experiment
data
demonstr
transfect
bladder
hepatocarcinoma
cell
line
dta
express
plasmid
control
hter
htert
regulatori
element
result
cytotox
accord
rel
activ
promot
element
cell
anoth
studi
express
dta
subcutan
inject
syngen
bladder
tumor
cell
line
mice
driven
previous
describ
gene
regulatori
sequenc
express
tumor
deriv
tissu
bladder
exhibit
gene
embryon
develop
intratumor
inject
dna
vector
calcium
phosphat
precipit
caus
signific
suppress
subcutan
tumor
growth
obviou
toxic
toward
host
signific
suppress
tumor
growth
anim
nearli
complet
ablat
tumor
two
human
patient
also
report
group
follow
intravesicl
bladder
administr
vector
also
show
high
kill
potenti
ovarian
cancer
cell
see
complex
transfect
enhanc
reagent
jetpei
appar
toxic
toward
host
observ
phase
iii
clinic
studi
patient
express
superfici
bladder
cancer
show
complet
respons
complet
marker
tumor
ablat
reduct
marker
lesion
six
treatment
vector
administr
intraves
complex
polyethyleneimin
dose
limit
toxic
observ
frequent
advers
event
mild
moder
bladder
discomfort
dysuria
micturit
urgenc
urinari
tract
infect
diarrhea
hypertens
asthenia
main
caus
acquir
immun
defici
syndrom
aid
studi
infecti
agent
last
year
hiv
retrovir
genom
carri
six
regulatori
gene
includ
tat
rev
vpr
vif
vpu
nef
gene
tat
encod
protein
play
key
role
control
product
process
viral
gene
transcript
tat
protein
bind
specif
sequenc
tar
transactiv
respons
element
locat
ltr
one
two
termin
repeat
segment
viral
genom
exert
effect
increas
rate
transcript
nascent
hiv
rna
viral
rev
protein
found
requir
express
viral
late
gene
product
bind
secondari
rna
structur
revrespons
element
rre
rev
protein
tether
partial
splice
unsplic
viral
rna
encod
late
viral
protein
cellular
nuclearexport
pathway
lead
enhanc
cytoplasm
level
rna
increas
express
encod
protein
appli
knowledg
viral
molecular
mechan
regul
gene
express
harrison
et
al
demonstr
use
combin
tat
rev
cisact
respons
sequenc
achiev
enhanc
express
transgen
cell
express
regulatori
transact
tat
rev
protein
maintain
low
basal
express
naiv
cell
substanti
impair
hiv
product
follow
hiv
provir
dna
transfect
hela
cell
contain
integr
hivregul
tatrev
respons
dta
gene
shown
subsequ
studi
tcell
line
transduc
recombin
retrovir
vector
encod
hiv
regul
wildtyp
attenu
dta
gene
also
show
substanti
longterm
impair
abil
produc
hiv
virion
upon
transfect
provir
dna
infect
laboratori
clinic
hiv
strain
use
construct
signific
protect
hiv
infect
depend
stock
use
dose
also
observ
cell
line
exhibit
mani
characterist
tissu
monocyt
serv
import
reservoir
viru
vivo
later
report
cotransfect
hiv
regul
dta
construct
hivdta
hiv
provir
dna
use
cation
liposomemedi
gene
deliveri
lipofect
could
prevent
viru
product
hela
cell
howev
although
hivregul
gene
found
express
transfect
chronic
hiv
infect
cell
transfect
hivdta
significantli
reduc
viru
product
alreadi
chronic
de
novo
hivinfect
cell
popul
probabl
due
low
percentag
lipofect
cell
matrix
metalloproteas
mmp
multigen
famili
zincdepend
endopeptidas
secret
latent
proenzym
capac
degrad
compon
extracellular
matrix
ecm
follow
activ
cleavag
addit
mmp
abil
process
molecul
growth
factor
receptor
adhes
molecul
proteinas
proteinas
inhibitor
mmp
basic
divid
distinct
subclass
accord
substrat
specif
cellular
local
secret
solubl
collagenas
gelatinas
stromelysin
matrilysin
membranetyp
mmp
integr
plasma
membran
protein
capabl
activ
mmp
certain
famili
member
includ
membraneassoci
mmp
activ
cleavag
achiev
intracellularli
proteas
furin
mmp
howev
activ
execut
extracellular
proteas
plasmin
mmp
restrict
small
number
normal
cell
sever
mmp
overexpress
differ
kind
solid
tumor
implic
ecm
degrad
associ
tumor
growth
angiogenesi
invas
anthrax
toxin
antx
major
virul
factor
secret
gramposit
sporeform
bacterium
bacillu
anthrachi
toxin
damag
cell
impair
host
defens
belong
famili
toxin
call
binari
toxin
character
consist
minim
two
discret
nontox
protein
must
combin
elicit
toxic
antx
consist
three
nontox
multidomain
protein
protect
antigen
paprag
kda
lethal
factor
lf
kda
edema
factor
ef
kda
review
see
intox
begin
bind
pa
either
two
known
cellular
receptor
pa
undergo
activ
cleavag
member
furin
famili
cellular
proteas
n
termin
kda
c
termin
kda
fragment
follow
cleavag
receptorbound
self
associ
form
ringshap
homoheptam
call
prepor
may
form
complex
three
molecul
lf
andor
ef
bound
lfef
molecul
occupi
two
neighbor
pa
subunit
result
complex
known
lethal
toxin
letx
edema
toxin
edtx
respect
intern
via
clathrindepend
receptormedi
endocytosi
deliv
earli
endosom
complex
sort
vesicular
region
preferenti
incorpor
intralumin
vesicl
subsequ
prepor
undergo
acid
phdepend
conform
chang
form
cationselect
ionconduct
channel
channelpor
thought
particip
unfold
lf
ef
function
transloc
lumen
intralumin
vesicl
cytoplasm
probabl
aid
cytosol
compon
follow
transport
late
endosom
back
fusion
intralumin
vesicl
limit
membran
deliv
toxic
factor
trap
insid
vesicl
lumen
cytoplasm
review
cellular
rout
anthrax
toxin
see
cytoplasm
lf
function
zinc
metalloproteinas
specif
cleav
ntermini
mkkmek
protein
kinas
mitogenactiv
protein
kinas
block
signal
activ
ef
activ
adenyl
cyclas
ac
act
elev
intracellular
level
cyclic
amp
camp
upset
water
homeostasi
destroy
delic
balanc
intracellular
signal
impair
neutrophil
function
figur
liu
et
al
first
introduc
appli
new
concept
replac
natur
furin
cleavag
site
anthrax
pa
protein
cleavag
must
occur
cell
surfac
order
achiev
bind
intern
catalyt
lf
ef
sequenc
recogn
proteas
may
confer
recombin
molecul
abil
target
proteas
overexpress
cell
end
two
mutat
pa
protein
name
also
natur
furin
recognit
site
replac
sequenc
suscept
cleavag
gelatinas
gelatinas
b
report
relat
invas
metastasi
variou
human
cancer
toxic
catalyt
polypeptid
use
studi
fusion
adpribosyl
domain
pseudomona
exotoxin
amino
acid
lf
lfn
contain
pa
bind
domain
prove
suffici
achiev
transloc
fuse
passeng
polypeptid
cytosol
cell
padepend
process
combin
reengin
pa
fusion
toxic
polypeptid
denot
research
demonstr
select
kill
mmpoverexpress
human
tumor
cell
line
spare
nontumorigen
normal
cell
protect
challeng
plu
mmp
inhibitor
demonstr
cell
kill
highli
depend
mmp
activ
express
tumor
cell
furthermor
specif
erad
mmp
overexpress
tumor
cell
cocultur
model
indic
pa
activ
occur
tumor
cell
surfac
cultur
supernat
activ
mmp
cell
membran
plasmin
andor
membraneanchor
mmp
togeth
bind
cell
surfac
receptor
propos
factor
may
contribut
retent
solubl
activ
mmp
surfac
tumor
cell
contrast
enzymat
activ
polypeptid
pe
dt
rip
strongli
inhibit
protein
synthesi
caus
death
intox
cell
see
inactiv
mitogenactiv
protein
kinas
kinas
action
anthrax
lethal
factor
lf
found
select
kill
cell
activ
mapk
pathway
requir
surviv
similar
observ
cell
bear
mutat
braf
serinethreonin
kinas
immedi
upstream
erk
mapk
cascad
mutat
demonstr
mainli
melanoma
also
human
malign
lock
molecul
constitut
activ
state
make
cell
depend
constitut
activ
erk
pathway
surviv
howev
although
specif
toxic
toward
braf
mutant
melanoma
cell
observ
vitro
xenograft
melanoma
tumor
mice
develop
letx
variant
lower
vivo
toxic
high
tumor
specif
would
requir
use
human
cancer
patient
purpos
use
lf
target
toxic
polypeptid
superior
specif
modifi
letx
compos
lf
mmp
activ
pa
protein
test
mice
xenograft
model
human
tumor
expect
show
lower
toxic
mice
wildtyp
toxin
potent
antitumor
activ
surprisingli
antitumor
activ
observ
human
melanoma
braf
mutat
due
direct
toxic
cell
also
human
tumor
type
includ
colon
lung
carcinoma
mous
tumor
regardless
braf
statu
tumor
histolog
vivo
angiogenesi
assay
suggest
effect
attribut
indirect
target
tumor
vasculatur
angiogen
process
express
mmp
shown
upregul
angiogen
lesion
mitogenactiv
protein
kinas
mapk
signal
pathway
play
central
role
later
vitro
studi
endotheli
prolifer
invas
tube
format
show
activ
letx
act
impair
microvascular
endotheli
cell
invas
migrat
absenc
endotheli
cell
death
anoth
intrigu
observ
administr
show
higher
antitumor
efficaci
wildtyp
toxin
probabl
greater
bioavail
longer
halflif
rel
pa
circul
treatment
also
delay
tumor
growth
improv
longterm
surviv
mice
orthotop
implant
anaplast
thyroid
carcinoma
atc
xenograft
antitumorogen
effect
compar
achiev
multikinas
inhibitor
sorafenib
current
evalu
clinic
use
patient
papillari
thyroid
carcinoma
ptc
alreadi
found
previou
studi
therapeut
effect
mediat
potent
antiangiogen
activ
drug
caus
signific
system
toxic
plasminogen
inact
precursor
plasmin
serin
proteas
present
plasma
extracellular
fluid
activ
process
fibrinolysi
degrad
extracellular
matrix
ecm
compon
one
natur
occur
plasminogen
activ
urokinasetyp
plasminogen
activ
upa
serin
proteas
secret
inact
proenzym
proupa
effici
convert
plasmin
kallikrein
upa
turn
cleav
plasminogen
gener
activ
plasmin
posit
feedback
mechan
catalyt
effici
reaction
increas
upon
bind
proupaupa
plasminogenplasmin
membran
receptor
result
reciproc
zymogen
activ
cell
surfac
initi
proteolyt
event
lead
initi
plasmin
gener
cell
surfac
still
studi
quit
restrict
normal
tissu
express
proupa
receptor
upar
found
elev
signific
number
solid
tumor
moreov
presenc
proteolyt
system
confer
tumor
mass
abil
degrad
ecm
protein
associ
increas
tumor
tissu
invas
metastat
potenti
target
tumor
cell
overexpress
urokinas
plasminogen
activ
system
furin
cleavag
site
anthrax
pa
protein
replac
sequenc
specif
cleav
upa
modifi
pa
combin
fusion
adpribosyl
domain
pseudomona
exotoxin
amino
acid
lf
see
presenc
proupa
plasminogen
recombin
complex
demonstr
activ
select
surfac
uparexpress
tumor
cell
broad
rang
human
cancer
differ
origin
ultim
result
specif
tumor
cell
erad
subsequ
vivo
studi
demonstr
effici
suppress
differ
murin
tumor
growth
erad
establish
tumor
limit
toxic
normal
tissu
upon
local
system
administr
complex
tumor
regress
complet
histolog
remiss
system
administr
toler
dose
document
vivo
athym
nude
mous
model
human
nonsmal
cell
lung
cancer
nsclc
requir
two
activ
proteolyt
event
two
differ
tumorassoci
proteas
may
confer
toxic
agent
superior
celltyp
specif
attenu
toxic
normal
tissu
eleg
work
perform
liu
et
al
intermolecular
complement
approach
use
target
tumor
cell
mmp
upa
activ
overproduc
tumor
tissu
implic
cancer
cell
growth
metastasi
end
author
exploit
find
anthrax
lf
bind
site
span
two
adjac
monom
cleav
pa
oligomer
prepor
monom
contain
three
subsit
play
role
bind
lf
howev
function
lf
bind
site
compos
combin
subsit
contribut
two
adjac
subunit
subsit
iii
form
one
monom
subsit
ii
neighbor
subunit
mutat
lf
bind
subsit
iii
mmp
activ
pa
subsit
ii
upa
activ
pa
assembl
pa
heptam
everi
lf
bind
site
contain
inactiv
subsit
iii
subsit
ii
mutat
occur
follow
activ
cleavag
either
mmp
upa
respect
howev
ad
mixtur
modifi
pa
protein
cell
mmp
upa
activ
would
gener
two
subunit
randomli
assembl
heptam
three
function
lf
bind
site
may
gener
intermolecular
complement
two
type
mutat
subunit
order
test
hypothesi
requir
two
tumorassoci
activ
proteolyt
event
may
attenu
toxic
normal
tissu
vivo
toxic
assay
mice
perform
intraperiton
administr
mixtur
contain
subsit
iii
mutat
subsit
ii
mutat
toxic
chimer
polypeptid
inde
result
show
decreas
toxic
comparison
administr
mixtur
either
mmp
upa
proteolyt
activ
suffici
gener
function
lf
bind
prepor
combin
evalu
treatment
three
mous
tumor
type
melanoma
fibrosarcoma
lewi
lung
carcinoma
strong
antitumor
activ
observ
contrast
tumor
show
littl
respons
treatment
individu
protein
demonstr
necess
intermolecular
complement
engin
paprag
protein
execut
potent
tumoricid
activ
antitumor
efficaci
compar
assay
combin
least
effect
equival
dose
howev
given
maximum
toler
dose
higher
complement
mixtur
achiev
higher
tumor
specif
halfliv
protein
live
cell
rang
second
mani
day
featur
protein
confer
metabol
instabl
call
degrad
signal
degron
nend
rule
degron
ndegron
first
discov
relat
vivo
halflif
protein
ident
aminotermin
residu
eukaryot
ndegron
compris
least
two
determin
destabil
ntermin
residu
intern
lysin
function
acceptor
site
format
multiubiquitin
chain
mark
ubiquitinprotein
conjug
substrat
proteosom
degrad
destabil
residu
mammalian
cell
hierarch
divid
three
class
primari
type
arg
ly
type
ile
leu
phe
tyr
trp
secondari
asp
glu
oxid
cy
tertiari
asn
gln
cy
review
comprehens
studi
faln
et
al
vivo
stabil
cytotox
diphtheria
toxinbas
polypeptid
artifici
modifi
initi
short
sequenc
deriv
flag
peptid
epitop
differ
ntermin
amino
acid
assess
accord
find
first
n
termin
amino
acid
modifi
toxin
phe
tyr
trp
asp
asn
glu
gln
ly
arg
protein
highli
unstabl
halfliv
rang
hour
toxin
initi
either
remain
amino
acid
consider
stabl
halfliv
rang
hour
vitro
studi
reticulocyt
lysat
indic
ten
n
termin
amino
acid
confer
toxin
short
vitro
half
life
also
destabil
one
vivo
moreov
cytotox
assay
vero
cell
show
clear
correl
vivo
stabil
cytotox
protein
although
differ
cytotox
wildtyp
dta
fragment
least
stabl
mutant
compar
differ
intracellular
halflif
alexand
varshavski
suggest
previous
construct
new
kind
toxin
signal
inactiv
toxin
eg
degrad
signal
cleav
viral
proteas
result
select
intox
viral
infect
cell
denot
toxin
sitoxin
signalregul
cleavag
mediat
toxin
construct
viralproteas
activ
sitoxin
faln
et
al
design
fusion
protein
compos
flag
peptid
contain
ntermin
phenylalanin
destabil
amino
acid
accord
nend
rule
follow
proteas
pr
cleavag
site
posit
upstream
chimer
sequenc
dta
first
pabind
amino
acid
anthrax
lf
lfn
fragment
also
shown
destabil
addit
degrad
signal
nendrulemedi
degrad
rational
behind
construct
follow
anthrax
pamedi
transloc
cytoplasm
uninfect
cell
modifi
toxin
would
rapidli
degrad
virtu
destabil
ndegron
result
attenu
cytotox
activ
uninfect
cell
contrast
cleavag
construct
proteas
whose
activ
document
cytosol
acut
infect
cell
would
result
remov
destabil
n
degron
chimer
toxin
expos
new
n
termin
amino
acid
hivpr
cleavag
two
recognit
sequenc
chosen
tatim
mqrg
vsqni
vivq
gener
stabil
n
termin
residu
methionin
valin
respect
accord
nend
rule
longlif
toxin
potent
cytotox
activ
gener
hiv
infect
cell
lead
destruct
inde
vitro
vivo
simul
experi
show
construct
predigest
hivpr
stabil
cytotox
chimer
toxin
consider
augment
prove
concept
stabil
protein
specif
proteolyt
remov
degrad
signal
work
practic
howev
select
erad
hiv
infect
cell
observ
follow
treatment
non
pretreat
construct
probabl
low
cytosol
pr
activ
proteolyt
process
construct
detect
hivinfect
cell
anoth
studi
perform
law
et
al
hiv
proteaseactiv
toxin
design
basi
type
iii
maiz
ribosomeinactiv
protein
nativ
form
synthes
inact
precursor
prorip
activ
proteolyt
remov
aminoacid
inhibitori
intern
peptid
inplanta
work
first
last
residu
intern
inactiv
region
replac
two
hivpr
recognit
sequenc
transduct
peptid
deriv
tat
protein
fuse
ntermini
modifi
rip
promot
cell
entri
modif
result
gener
prorip
underw
effici
cleavag
vitro
recombin
hivpr
vivo
hiv
infect
cell
viral
encod
proteas
upon
treatment
infect
cell
antivir
activ
modifi
cleavabl
rip
found
higher
uncleavablenonactiv
prorip
resembl
activ
mutant
inhibitori
region
genet
remov
cytotox
activ
cleavabl
rip
infect
cell
report
cytotox
toward
uninfect
cell
found
lower
activ
mutant
thu
fact
cleavabl
toxin
behav
like
constitut
activ
form
toward
infect
cell
similar
way
nonactiv
form
toward
uninfect
cell
may
suggest
specif
activ
hiv
proteas
demonstr
possibl
use
cleavabl
intern
inactiv
region
switch
activ
toxin
insid
infect
cell
treat
cancer
chronic
viral
infect
among
challeng
goal
modern
medicin
recent
integr
modifi
plant
bacteri
toxin
base
therapi
particularli
immunotoxin
antitumor
activ
clinic
research
applic
add
new
weapon
arsen
refractori
diseas
cumul
knowledg
toxin
structur
mechan
action
well
recent
progress
breakthrough
field
cell
biolog
immunolog
virolog
molecular
biolog
nanotechnolog
enabl
develop
differ
target
strategi
crucial
convert
lethal
toxin
therapeut
agent
see
figur
howev
clinic
applic
engin
toxin
still
face
mani
challeng
two
major
problem
associ
system
administr
immunotoxin
lack
specif
result
presenc
target
antigenreceptor
also
present
healthi
tissu
target
depend
toxic
undesir
intox
healthi
tissu
due
immunotoxin
bind
cell
surfac
compon
rather
specif
target
antigenreceptor
target
independ
toxic
wherea
first
problem
directli
relat
target
expressionbodydistribut
profil
second
relat
natur
therapeut
agent
common
toxic
patient
treat
immunotoxin
vascular
leak
syndrom
vl
hepatotox
caus
nonspecif
bind
toxic
target
moieti
immunotoxin
endotheli
hepat
cell
respect
review
see
regard
issu
baluna
et
al
found
sequenc
three
amino
acid
ricin
toxin
protein
associ
vascular
leak
syndrom
might
caus
endotheli
damag
mechan
involv
disrupt
integrin
independ
classic
cell
kill
mediat
toxin
enzymat
activ
screen
panel
recombin
ricin
chain
mutat
sequenc
amino
acid
flank
threedimension
structur
mutant
form
rta
show
diminish
vl
mice
isol
pharmacokinet
issu
nonspecif
toxic
common
problem
associ
develop
mani
drug
particularli
develop
chemotherapeut
agent
immunogen
major
challeng
distinguish
immunotoxin
small
moleculebas
therapi
immunotoxin
gener
contain
least
one
nonhuman
compon
might
bacterialpl
deriv
toxic
moieti
andor
antibodi
anim
origin
consequ
antidrug
antibodi
format
may
induc
immunecompet
patient
result
compromis
treatment
effici
caus
decreas
level
circul
function
agent
issu
humananti
mous
antibodi
hama
format
immunotoxin
target
moieti
monoclon
antibodi
produc
hybridoma
cell
overcom
great
extent
develop
chimer
human
fulli
human
antibodi
use
recombin
dna
technolog
review
attempt
use
polyethylen
glycol
pegyl
immunosuppress
agent
led
differ
success
rate
reduc
immunogen
respons
nonhuman
compon
immunotoxin
delet
bcell
epitop
locat
surfac
toxic
moieti
anoth
option
reduc
immunogen
recent
studi
conduct
onda
et
al
reveal
seven
major
conform
bcell
epitop
molecul
mutat
specif
larg
hydrophil
amino
acid
surfac
compon
immunotoxin
see
b
cell
epitop
elimin
new
fulli
function
immunotoxin
significantli
less
immunogen
mice
creat
take
advantag
knowledg
oh
et
al
creat
bispecif
cytotox
polypeptid
human
epiderm
growth
factor
egf
link
bcell
epitopesdelet
administr
mous
model
metastat
breast
carcinoma
immunogen
reduc
comparison
nonmut
construct
appar
loss
antitumor
activ
concern
proteas
activ
toxin
toxin
base
suicid
gene
therapi
clinic
data
scarc
develop
field
evalu
clinic
howev
conceiv
specif
issu
remain
relev
also
agent
transcript
proteolyt
activ
execut
toxic
rare
associ
exclus
diseas
cell
rather
previous
mention
also
physiolog
role
healthi
tissu
case
immunotoxin
immunogen
may
also
problem
must
overcom
treat
immunocompet
patient
proteas
activ
toxin
toxin
base
suicid
gene
therapi
either
immunogen
cleavabl
toxin
immunogen
viral
vecto
conclus
toxinbas
therapi
versatil
dynam
research
area
great
applic
potenti
demonstr
review
howev
research
requir
order
improv
effici
safeti
toxinbas
agent
invest
develop
deliveri
target
techniqu
definit
requir
order
achiev
goal
nevertheless
basic
research
structur
mechan
natur
toxin
abandon
deeper
knowledg
uniqu
famili
secret
polypeptid
easier
us
har
great
potenti
benefit
